MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
Progyny Revenue 2011-2026 | PGNY
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Progyny
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 298 M | 270 M | 787 M | 501 M | 345 M | 230 M | 105 M | 48.6 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 787 M | 48.6 M | 323 M |
Quarterly Revenue Progyny
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 313 M | 333 M | 324 M | - | 287 M | 304 M | 278 M | - | 281 M | 279 M | 258 M | - | 205 M | 195 M | 172 M | 128 M | 122 M | 129 M | 122 M | 100 M | 98.9 M | 64.6 M | 81 M | 65.1 M | 61.2 M | 56.2 M | 47.2 M | 29.2 M | 27.8 M | 26.2 M | 22.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 333 M | 22.3 M | 158 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Health information services industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cerner Corporation
CERN
|
5.76 B | - | - | $ 27.9 B |  USA |
 |
Change Healthcare
CHNG
|
3.09 B | - | - | $ 9.03 B | USA |
 |
Computer Programs and Systems
CPSI
|
339 M | - | 4.4 % | $ 133 M | USA |
 |
Covetrus
CVET
|
4.58 B | - | - | $ 2.94 B | USA |
 |
Accolade
ACCD
|
170 M | - | 0.29 % | $ 206 M | USA |
 |
Castlight Health, Inc.
CSLT
|
147 M | - | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
673 M | - | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
668 M | - | - | $ 6.37 B | USA |
 |
OptimizeRx Corporation
OPRX
|
71.5 M | $ 13.05 | -2.36 % | $ 223 M | USA |
 |
Health Catalyst
HCAT
|
307 M | $ 2.46 | 0.41 % | $ 148 M | USA |
 |
Phreesia
PHR
|
356 M | $ 17.33 | 2.54 % | $ 946 M | USA |
 |
Evolent Health
EVH
|
382 M | $ 4.18 | 0.6 % | $ 392 M | USA |
 |
HealthStream
HSTM
|
292 M | $ 22.12 | -0.83 % | $ 672 M | USA |
 |
iCAD
ICAD
|
19.6 M | - | - | $ 102 M | USA |
 |
Akerna Corp.
KERN
|
20.5 M | - | - | $ 161 M | USA |
 |
10x Genomics
TXG
|
619 M | $ 20.58 | 6.66 % | $ 2.41 B | USA |
 |
HealthEquity
HQY
|
262 M | $ 94.6 | -3.97 % | $ 8.09 B | USA |
 |
American Well Corporation
AMWL
|
254 M | $ 5.11 | -1.16 % | $ 76.6 M | USA |
 |
Premier
PINC
|
263 M | $ 28.26 | - | $ 2.33 B | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
1.5 B | - | -10.39 % | $ 886 M | USA |
 |
MTBC
MTBC
|
111 M | - | -0.58 % | $ 51.7 M | USA |
 |
So-Young International
SY
|
-1.52 M | $ 2.64 | 0.96 % | $ 210 M |  China |
 |
GoodRx Holdings
GDRX
|
792 M | $ 2.8 | 0.18 % | $ 1.08 B | USA |
 |
Omnicell
OMCL
|
1.11 B | $ 51.16 | 1.13 % | $ 2.36 B | USA |
 |
1Life Healthcare
ONEM
|
623 M | - | - | $ 3.37 B | USA |
 |
Veeva Systems
VEEV
|
2.36 B | $ 241.36 | 0.08 % | $ 38.7 B | USA |
 |
R1 RCM
RCM
|
1.47 B | - | - | $ 3.81 B | USA |
 |
Zhongchao
ZCMD
|
16.3 M | $ 0.56 | 5.9 % | $ 2.92 M | China |
 |
NantHealth
NH
|
67 M | - | -46.64 % | $ 10.4 M | USA |
 |
Schrödinger
SDGR
|
208 M | $ 18.34 | -1.48 % | $ 1.33 B | USA |
 |
NextGen Healthcare
NXGN
|
557 M | - | - | $ 1.6 B | USA |
 |
Signify Health
SGFY
|
184 M | - | -0.02 % | $ 7.21 B | USA |
 |
Streamline Health Solutions
STRM
|
17.9 M | - | - | $ 21.4 M | USA |
 |
Teladoc Health
TDOC
|
2.57 B | $ 7.44 | -2.3 % | $ 1.27 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
300 M | - | - | $ 255 M | USA |
 |
SCWorx Corp.
WORX
|
2.99 M | $ 0.2 | 0.1 % | $ 292 K | USA |